NasdaqGM - Delayed Quote USD
CRISPR Therapeutics AG (CRSP)
39.25
+0.57
+(1.47%)
At close: May 20 at 4:00:01 PM EDT
39.11
-0.14
(-0.36%)
Pre-Market: 7:57:22 AM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 18 | 18 | 24 | 23 |
| Avg. Estimate | -1.46 | -1.32 | -5.42 | -4.37 |
| Low Estimate | -2.27 | -1.68 | -6.71 | -6.82 |
| High Estimate | -0.93 | -1.04 | -3.81 | 2.55 |
| Year Ago EPS | -1.49 | -1.01 | -4.34 | -5.42 |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 17 | 16 | 24 | 22 |
| Avg. Estimate | 6.74M | 13.42M | 51.86M | 198.27M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | 31.07M | 44.33M | 143M | 1.48B |
| Year Ago Sales | 517k | 602k | 37.31M | 51.86M |
| Sales Growth (year/est) | 1,204.34% | 2,128.53% | 38.97% | 282.35% |
Earnings History
| Currency in USD | 6/30/2024 | 9/30/2024 | 12/31/2024 | 3/31/2025 |
|---|---|---|---|---|
| EPS Est. | -1.43 | -1.4 | -1.19 | -1.28 |
| EPS Actual | -1.49 | -1.01 | -0.44 | -1.58 |
| Difference | -0.06 | 0.39 | 0.75 | -0.3 |
| Surprise % | -4.44% | 28.11% | 62.89% | -23.75% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -1.46 | -1.32 | -5.42 | -4.37 |
| 7 Days Ago | -1.38 | -1.32 | -5.36 | -4.36 |
| 30 Days Ago | -1.26 | -1.23 | -4.91 | -4 |
| 60 Days Ago | -1.28 | -1.25 | -4.89 | -3.96 |
| 90 Days Ago | -1.28 | -1.25 | -4.9 | -3.92 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | 6 | 7 | 6 | 7 |
| Up Last 30 Days | 6 | 7 | 6 | 7 |
| Down Last 7 Days | 10 | 8 | 12 | 9 |
| Down Last 30 Days | 10 | 8 | 13 | 10 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| CRSP | 2.34% | -30.76% | -24.86% | 19.36% |
| S&P 500 | 13.32% | 2.69% | 7.77% | 13.75% |
Upgrades & Downgrades
| Reiterates | Needham: Buy to Buy | 5/20/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/20/2025 |
| Maintains | Barclays: Equal-Weight to Equal-Weight | 5/9/2025 |
| Maintains | Goldman Sachs: Neutral to Neutral | 5/8/2025 |
| Maintains | Needham: Buy to Buy | 5/7/2025 |
| Maintains | Chardan Capital: Buy to Buy | 5/7/2025 |
Related Tickers
NTLA Intellia Therapeutics, Inc.
9.67
+6.73%
VRTX Vertex Pharmaceuticals Incorporated
447.18
+1.48%
EDIT Editas Medicine, Inc.
1.6400
+10.07%
BEAM Beam Therapeutics Inc.
17.75
+0.54%
RXRX Recursion Pharmaceuticals, Inc.
4.5500
+0.89%
MRNA Moderna, Inc.
27.99
+6.06%
VKTX Viking Therapeutics, Inc.
28.67
+4.25%
REGN Regeneron Pharmaceuticals, Inc.
614.79
+3.21%
SRPT Sarepta Therapeutics, Inc.
39.99
+5.40%
BLUE bluebird bio, Inc.
4.9800
0.00%